In animal models of obesity, administration of dual GLP‐1R/GCGR agonists resulted in superior weight loss, lower glucose levels, and reduced food intake compared with pure GLP‐1R agonists alone.118, 119, 120, 121. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.